SCHEMBL14659785

SCHEMBL14659785

CCOC(=O)c1nn(-c2ccccc2Br)c(=O)c2c(N)scc12

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.81
▸ ALDH1A1 P00352 5/20 0.81
▸ KDM4E B2RXH2 4/20 0.81
▸ ADORA1 P30542 11/20 0.74
▸ ALOX12 P18054 3/20 0.74
▸ CASP1 P29466 2/20 0.74
▸ ALOX15 P16050 2/20 0.74
▸ HSD17B10 Q99714 2/20 0.74
▸ APP P05067 6/20 0.66
▸ MEN1 O00255 1/20 0.66
▸ KMT2A Q03164 1/20 0.66
▸ L3MBTL1 Q9Y468 1/20 0.66
▸ APAF1 O14727 1/20 0.65
▸ CACNA1B Q00975 1/20 0.65
▸ APBA1 Q02410 1/20 0.65
▸ MAPK1 P28482 1/20 0.65
▸ CASP6 P55212 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14659712 0.90 MAPT (1.00) MAPTALDH1A1KDM4EADORA1ALOX12
SCHEMBL14659751 0.89 MAPT (0.83) MAPTALDH1A1KDM4EADORA1ALOX12
SCHEMBL1491895 0.88 MAPT (1.00) MAPTALDH1A1KDM4EADORA1ALOX12
SCHEMBL1491898 0.88 MAPT (0.81) MAPTALDH1A1KDM4EADORA1ALOX12
SCHEMBL14659674 0.86 MAPT (0.79) MAPTALDH1A1KDM4EADORA1ALOX12
SCHEMBL7885074 0.85 MAPT (1.00) MAPTALDH1A1KDM4EADORA1ALOX12
SCHEMBL14659677 0.84 ADORA1 (0.81) MAPTALDH1A1KDM4EADORA1ALOX12
SCHEMBL1491896 0.84 MAPT (0.84) MAPTALDH1A1KDM4EADORA1ALOX12
SCHEMBL8166334 0.83 MAPT (0.94) MAPTALDH1A1KDM4EADORA1ALOX12
SCHEMBL14660061 0.81 MAPT (0.88) MAPTALDH1A1KDM4EADORA1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029983-A1 AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2013-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029983-A1 AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY MAPT, PSEN1, PSEN2 MAPT 1/4885ALDH1A1 2295/4885KDM4E 2737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback